{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166182823",
    "name" : "Annotation of DPWG Guideline for eliglustat and CYP2D6",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : true,
    "hasTestingInfo" : true,
    "history" : [
      {
        "id" : 1450415100,
        "date" : "2019-05-23T21:23:23.388-07:00",
        "description" : "Annotation current with November 2018 DPWG Guideline release",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450820792,
        "date" : "2019-10-06T23:12:58.685-07:00",
        "description" : "No changes based on August 2019 guideline",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450962920,
        "date" : "2020-02-10T11:39:18.674-08:00",
        "description" : "Fixed links to 2018 guideline pdfs.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451431320,
        "date" : "2021-05-04T00:00:00-07:00",
        "description" : "Added extended dosing",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451704163,
        "date" : "2022-03-03T16:33:20.285-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451732803,
        "date" : "2022-03-28T09:57:34.076-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451884231,
        "date" : "2022-09-16T10:08:25.137-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084384,
        "date" : "2023-04-28T18:51:44.339-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084405,
        "date" : "2023-04-28T18:51:57.776-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084426,
        "date" : "2023-04-28T18:52:07.976-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084447,
        "date" : "2023-04-28T18:52:19.757-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084468,
        "date" : "2023-04-28T18:52:49.135-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084489,
        "date" : "2023-04-28T18:53:07.319-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084510,
        "date" : "2023-04-28T18:53:23.364-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084531,
        "date" : "2023-04-28T18:53:40.980-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084552,
        "date" : "2023-04-28T18:54:03.533-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084573,
        "date" : "2023-04-28T18:56:19.950-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084604,
        "date" : "2023-04-28T19:05:03.333-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146460,
        "date" : "2023-07-03T13:39:50.879-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452411806,
        "date" : "2024-03-18T12:10:36.826-07:00",
        "description" : "Updated links for risk analysis pdf and preemptive testing page. Checked box for testing.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1454247740,
        "date" : "2025-09-08T15:08:01.647-07:00",
        "description" : "updated based on version 20240101",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","crossReferences":[{"id":1450815695,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","crossReferences":[{"id":1450415575,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15184982,"title":"Dutch Pharmacogenetics Working Group Guidelines September 2025","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/pharmacogenetic_recommendation_text_20240101_downloaded_090825.pdf","crossReferences":[{"id":1454247640,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/pharmacogenetic_recommendation_text_20240101_downloaded_090825.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/pharmacogenetic_recommendation_text_20240101_downloaded_090825.pdf"}],"objCls":"Literature","terms":[{"id":1452267780,"resource":"ClinPGx Tags","term":"Has PGx","termId":"pgkbTags:1452267780"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : true,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA166123486",
        "name" : "eliglustat",
        "version" : 5
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA128",
        "symbol" : "CYP2D6",
        "name" : "cytochrome P450 family 2 subfamily D member 6",
        "version" : 7891
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1450415099,
      "html" : "<p>The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for renal and hepatic impairment.</p>\n",
      "version" : 2
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1450415097,
      "html" : "<h3 id=\"september-2025-update\">September 2025 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (<a href=\"/page/dpwg\">DPWG</a>) released an updated version of the <a download=\"pharmacogenetic_recommendation_text_20240101_downloaded_090825.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/pharmacogenetic_recommendation_text_20240101_downloaded_090825.pdf\">Pharmacogenetic_recommendation_text</a> dated with 20240101. It includes changes to the wording for the CYP2D6-eliglustat guidelines which are dated within the document as 6-11-2023.</p>\n<p><em>Wording in table taken from the DPWG <a download=\"pharmacogenetic_recommendation_text_20240101_downloaded_090825.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/pharmacogenetic_recommendation_text_20240101_downloaded_090825.pdf\">Pharmacogenetic_recommendation_text</a> accessed 09082025</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2D6 UM</td>\n<td>eliglustat</td>\n<td>The normal dose is not effective. The gene variation increases the conversion of eliglustat into inactive metabolites. There are insufficient data to determine an effective dose for all UM.</td>\n<td>Eliglustat is contraindicated.<br/>Avoid eliglustat</td>\n</tr>\n<tr>\n<td>CYP2D6 IM</td>\n<td>eliglustat</td>\n<td>The gene variation reduces the conversion of eliglustat into inactive metabolites. However, in the absence of renal and hepatic impairment, this does not lead to a clinically significant increased risk of adverse reactions.</td>\n<td>- MILD, MODERATE OR SEVERE RENAL IMPAIRMENT and/or MILD HEPATIC IMPAIRMENT:<br/>Eliglustat is not recommended. avoid eliglustat if possible.<br/>OTHER:<br/>- no action required (i.e. same treatment as for normal metabolisers)</td>\n</tr>\n<tr>\n<td>CYP2D6 PM</td>\n<td>eliglustat</td>\n<td>The gene variation reduces the conversion of eliglustat into inactive metabolites. This increases the risk of adverse reactions, such as a (small, dose-dependent) prolongation of the QT interval. CYP3A inhibitors and kidney and liver impairment further increase this risk.</td>\n<td>- Co-medication with a STRONG CYP3A INHIBITOR (e.g. ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):<br/>Eliglustat is contraindicated. - avoid eliglustat<br/>- Co-medication with a MODERATE CYP3A INHIBITOR (e.g. erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):<br/>Eliglustat is not recommended. - avoid eliglustat if possible<br/>- Co-medication with a WEAK CYP3A INHIBITOR (e.g. amlodipine, cilostazol, fluvoxamine, goldenseal, isoniazid, ranitidine, ranolazine):<br/>- avoid the weak CYP3A inhibitor if possible<br/>- if avoidance is not possible: - use a dose of 84 mg eliglustat once daily - be alert for adverse reactions<br/>- Co-medication with a STRONG CYP3A INDUCTOR (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutin, hypericum):<br/>Eliglustat is not recommended. Plasma concentrations may decrease to such an extent that a therapeutic effect is not achieved. - avoid eliglustat if possible<br/>Note: This advice does not differ from that for normal metabolisers.<br/>- KIDNEY and/or LIVER IMPAIRMENT:<br/>Eliglustat is not recommended. - avoid eliglustat if possible<br/>Note: This advice differs from that for normal metabolisers only in case of mild, moderate or severe kidney impairment and mild liver impairment.<br/>- NO co-medication with a CYP3A inhibitor or strong CYP3A inducer and NO kidney and liver impairment:<br/>- use a dose of 84 mg once daily.</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_CYP2D6-eliglustat_5704-6.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/DPWG_CYP2D6-eliglustat_5704-6.pdf\">Read for more information about this recommendation</a>, <a download=\"CYP2D6.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/CYP2D6.pdf\">Read about gene information from DPWG</a></p>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a download=\"DPWG_CYP2D6_eliglustat_6137-6138-6139.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/DPWG_CYP2D6_eliglustat_6137-6138-6139.pdf\">DPWG risk analysis document</a> for eliglustat and CYP2D6:</p>\n<blockquote class=\"blockquote\">\n<p>Due to the absence of publications of new clinical studies or case reports with patients with a CYP2D6 genotype\nleading to reduced or increased CYP2D6 activity in medical journals, and thus the absence of evidence of an\nincrease in adverse events code ≥ D (grade ≥ 3) in these patients, the clinical implication of the gene-drug interaction\nscores only 2 out of the maximum of 10 points (with pre-emptive genotyping considered to be potentially beneficial for\nscores ranging from 0 to 2 points) (see also the Clinical Implication Score tables at the end of this risk analysis).\nHowever, there is not enough evidence to reject the warnings and recommendations in the SmPC. In addition, the\nClinical Implication Score is mainly (for 80%) based on studies published in medical journals and therefore not suited\nto determine the clinical implication for gene-drug interactions for which data are only provided by pre-registration\nstudies. For these reasons, the KNMP Pharmacogenetics Working Group decided to ignore the Clinical Implication\nScore and adopt the genotyping recommendation in the SmPC. The SmPC indicates that genotyping must be performed before starting eliglustat to guide drug and dose selection. This would amount to genotyping being essential for\ndrug safety according to the nomenclature of the KNMP Pharmacogenetics Working Group.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<h3 id=\"november-2018-guideline\">November 2018 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for eliglustat based on CYP2D6 genotype. They recommend to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers, recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CPY3A inducers.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_November_2018.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a></em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2D6 UM</td>\n<td>eliglustat</td>\n<td>This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM.</td>\n<td>Eliglustat is contra-indicated. Choose an alternative if possible.</td>\n</tr>\n<tr>\n<td>CYP2D6 IM</td>\n<td>eliglustat</td>\n<td>This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects.</td>\n<td>- Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR: Eliglustat is contra-indicated.<br/>1. Choose an alternative if possible.<br/>Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.<br/>&nbsp;<br/>- Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):<br/>1. Use a dose of 84mg eliglustat 1x daily.<br/>&nbsp;<br/>- Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):<br/>1. Consider a dose of 84mg eliglustat 1x daily.<br/>2. Be alert to side effects.<br/>&nbsp;<br/>- Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):<br/>1. Choose an alternative if possible.<br/>2. If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.<br/>&nbsp;<br/>- Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):<br/>1. Choose an alternative.<br/>2. If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.<br/>&nbsp;<br/>- Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.<br/>1. Choose an alternative if possible.<br/>&nbsp;<br/>- NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:<br/>1. Use the standard dose of 84mg 2x daily.</td>\n</tr>\n<tr>\n<td>CYP2D6 PM</td>\n<td>eliglustat</td>\n<td>This gene variation reduces the conversion of eliglustat to inactive metabolites. This increases the risk of side effects, such as a (small, dose-dependent) elongation of the QT interval. CYP3A inhibitors increase this risk even further.</td>\n<td>- Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir): Eliglustat is contra-indicated.<br/>1. Choose an alternative if possible.<br/>&nbsp;<br/>- Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine): Eliglustat is not recommended.<br/>1. Choose an alternative if possible.<br/>&nbsp;<br/>- Co-medication with a WEAK CYP3A INHIBITOR (for example amlopidine, cilostazole, fluvoxamine, goldenseal, isoniazide, ranitidine, ranolazine):<br/>1. Choose an alternative for the weak CYP3A inhibitor if possible.<br/>2. If an alternative is not an option: Use a dose of 84mg eliglustat 1x daily and be alert to side effects.<br/>&nbsp;<br/>- Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.<br/>1. Choose an alternative if possible.<br/>&nbsp;<br/>- NO co-medication with a CYP3A inhibitor or strong CYP3A inducer:<br/>1. Use a dose of 84mg 1x daily.</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_CYP2D6_eliglustat_6137-6138-6139.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/DPWG_CYP2D6_eliglustat_6137-6138-6139.pdf\">Read for more information about this recommendation</a>, <a download=\"CYP2D6.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/CYP2D6.pdf\">Read about gene information from DPWG</a></p>\n",
      "version" : 7
    },
    "version" : 16
  }
}